Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
16
pubmed:dateCreated
2001-11-5
pubmed:abstractText
Chronic administration of antidepressants has been shown to reduce the number of escape failures in the rat learned helplessness test (LH). In the present study we investigated the role of D1, D2 and D3 receptors in mediating this effect. In our first series of experiments, we demonstrated that SKF38393, D1 receptor agonist, in a dose of 2.5 mg/kg (i.p.) and quinpirole, D2 receptor agonist in a dose of 0.5 mg/kg (i.p.), significantly decreased the number of escape failures in LH, and these were reversed by SCH23390 (0.015 mg/kg), D1 receptor antagonist, and by sulpiride (25 mg/kg), D2 receptor antagonist, respectively. In contrast, 7-OH-DPAT, a D3 receptor agonist, in a dose of 10 mg/kg (i.p.) did not affect the number of escape failures in LH. In a second series of experiments, we showed that eight days of repeated treatment with imipramine (10 mg/kg, p.o.), fluvoxamine (1.25 mg/kg, p.o.) and tranylcypromine (1.25 mg/kg, p.o.) significantly decreased the number of escape failures in LH. The decrease in escape failures seen with use of imipramine and tranylcypromine was reversed by sulpiride in LH, but not by SCH23390. On the other hand, the effect of fluvoxamine was reversed by both SCH23390 and sulpiride. These findings indicate that stimulation of D1 and D2 receptors decreased the number of escape failures in LH, respectively. Thus, D2 and/or D1 receptors are probably involved in the decreased number of escape failures in case of repeated treatment with antidepressants in LH.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
http://linkedlifedata.com/resource/pubmed/chemical/2,3,4,5-Tetrahydro-7,8-dihydroxy-1-p..., http://linkedlifedata.com/resource/pubmed/chemical/7-hydroxy-2-N,N-dipropylaminotetrali..., http://linkedlifedata.com/resource/pubmed/chemical/Antidepressive Agents, http://linkedlifedata.com/resource/pubmed/chemical/Benzazepines, http://linkedlifedata.com/resource/pubmed/chemical/Dopamine Agonists, http://linkedlifedata.com/resource/pubmed/chemical/Dopamine Antagonists, http://linkedlifedata.com/resource/pubmed/chemical/Fluvoxamine, http://linkedlifedata.com/resource/pubmed/chemical/Imipramine, http://linkedlifedata.com/resource/pubmed/chemical/Quinpirole, http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Dopamine, http://linkedlifedata.com/resource/pubmed/chemical/Sulpiride, http://linkedlifedata.com/resource/pubmed/chemical/Tetrahydronaphthalenes, http://linkedlifedata.com/resource/pubmed/chemical/Tranylcypromine
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
0024-3205
pubmed:author
pubmed:issnType
Print
pubmed:day
7
pubmed:volume
69
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1919-26
pubmed:dateRevised
2008-11-21
pubmed:meshHeading
pubmed-meshheading:11693272-2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine, pubmed-meshheading:11693272-Animals, pubmed-meshheading:11693272-Antidepressive Agents, pubmed-meshheading:11693272-Benzazepines, pubmed-meshheading:11693272-Disease Models, Animal, pubmed-meshheading:11693272-Dopamine Agonists, pubmed-meshheading:11693272-Dopamine Antagonists, pubmed-meshheading:11693272-Escape Reaction, pubmed-meshheading:11693272-Fluvoxamine, pubmed-meshheading:11693272-Helplessness, Learned, pubmed-meshheading:11693272-Imipramine, pubmed-meshheading:11693272-Male, pubmed-meshheading:11693272-Quinpirole, pubmed-meshheading:11693272-Rats, pubmed-meshheading:11693272-Rats, Wistar, pubmed-meshheading:11693272-Receptors, Dopamine, pubmed-meshheading:11693272-Sulpiride, pubmed-meshheading:11693272-Tetrahydronaphthalenes, pubmed-meshheading:11693272-Tranylcypromine
pubmed:year
2001
pubmed:articleTitle
Repeated treatment with imipramine, fluvoxamine and tranylcypromine decreases the number of escape failures by activating dopaminergic systems in a rat learned helplessness test.
pubmed:affiliation
CNS Diseases Research, Laboratory-1, Medicinal Research Laboratories, Taisho Pharmaceutical Co., Ltd., Ohmiya, Saitama, Japan. s17525@ccm.taisho.co.jp
pubmed:publicationType
Journal Article